TLP Group’s Adaptimmune Therapeutics ADAP Stock Holding History

TLP Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,311	Closed	-$94K	–	256
2016 Q3	$94K	Buy	+13,311	New	+$102K	0.1%	218

Other funds holding ADAP

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

TLP Group's ADAP Position: Q4 2016 in Review

TLP Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2016, closing a stake of 13,311 shares — an estimated $94K sold.

TLP Group first reported a position in ADAP in Q3 2016 and held it in 1 quarter. The position peaked at $94K in Q3 2016. 40 funds tracked by Wall St. Rank hold ADAP as of Q4 2016.

TLP Group reported no remaining Adaptimmune Therapeutics position as of Q4 2016 after selling out during the quarter.
TLP Group sold 13,311 Adaptimmune Therapeutics shares in Q4 2016, an estimated $94K.
TLP Group first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 1 quarter.
TLP Group's Adaptimmune Therapeutics position peaked at $94K in Q3 2016.
40 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.